Greenlight Capital, an investment management company, released its Q1 2026 investor letter. In Q1 2026, the Greenlight Capital funds (the “Partnerships”) returned 6.5%, net of fees and expenses, compared to -4.4% for the S&P 500 index. A copy of the letter can be downloaded here. Fundamentally, trading depends on predicting stock movements. Lessons from the financial crisis highlighted the importance of macroeconomic analysis, prompting Greenlight to adopt ‘top-down’ as well as ‘bottom-up’ strategies, including macro instruments based on broader predictions. However, major events push research beyond securities or economic analysis, as seen with the Iran war, which is unpredictable. Most investors currently expect positive outcomes; the market recovered after the ceasefire, showing confidence in peace. In this environment, the firm maintains low exposure, focusing on capital preservation and cautiously considering recovery opportunities. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Greenlight Capital highlighted Acadia Healthcare Company, Inc. (NASDAQ:ACHC) as leading contrubutor. Incorporated in 2005, Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is a behavioral healthcare services provider. On April 23, 2026, Acadia Healthcare Company, Inc. (NASDAQ:ACHC) stock closed at $27.34 per share. One-month return of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) was 19.34%, and its shares gained 23.43% over the past twelve months. Acadia Healthcare Company, Inc. (NASDAQ:ACHC) has a market capitalization of $2.52 billion.
Greenlight Capital stated the following regarding Acadia Healthcare Company, Inc. (NASDAQ:ACHC) in its Q1 2026 investor letter:
“Our significant winners in the quarter were gold, Acadia Healthcare Company, Inc. (NASDAQ:ACHC), DHT Holdings (DHT) and Core Natural Resources (CNR). ACHC is the leading pure-play behavioral healthcare clinic operator in the U.S. After peaking near $90 in 2022, the stock came under heavy pressure in late 2024 following a New York Times investigation that revealed poor and sometimes abusive treatment of patients. While we bought a small position at the time around $51 per share, this proved to be only the beginning of ACHC’s challenges. Due to an overly aggressive expansion strategy and an inability to manage its patient ramp, ACHC had occupancy challenges that weighed on results, while litigation expenses were growing. ACHC shares ultimately bottomed out at around $11 in January.
Our work suggested the problems were entirely management-related and that ACHC’s asset quality is strong. Early this year we increased our position, believing that a leadership change was probable. Ultimately, our average entry price for what is now a top 5 position is $16.24 per share.
In January, the company replaced its CEO, bringing back the former CEO who ran the company successfully from 2018 to 2022. The returning CEO is among the most well-regarded and capable operators in the industry. With this injection of confidence and competence, the shares recovered to $23.39 by the end of the quarter. Should the company achieve stabilized occupancy, we believe it would earn over $3 per share.”
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 44 hedge fund portfolios held Acadia Healthcare Company, Inc. (NASDAQ:ACHC) at the end of the fourth quarter, up from 40 in the previous quarter. While we acknowledge the risk and potential of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Acadia Healthcare Company, Inc. (NASDAQ:ACHC) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Acadia Healthcare Company, Inc. (NASDAQ:ACHC) and shared a bullish thesis on the company. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
